PET/CT improves survival in lung cancer patients
Patients who undergo PET/CT exams prior to surgery for non-small cell lung cance...Read more on AuntMinnie.comRelated Reading: CT lung cancer screening saved more than 10K lives PET tracer proves effective for assessing immunotherapy Quitting smoking slows early lung cancer progression CT radiomics predicts survival in NSCLC patients (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - June 24, 2022 Category: Radiology Source Type: news

Income, Education Linked to Advanced Stage of Diagnosis of NSCLC
MONDAY, June 20, 2022 -- Area-level income and education are associated with the diagnosis of non-small cell lung cancer (NSCLC) at an advanced stage, according to a study published online June 20 in Cancer. Anjali Gupta, from Duke University in... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 20, 2022 Category: Pharmaceuticals Source Type: news

Immunotherapy Charts New Course for Resectable NSCLC Treatment Immunotherapy Charts New Course for Resectable NSCLC Treatment
Three cycles of neoadjuvant nivolumab plus chemotherapy improved long-term clinical outcomes in patients with resectable stage IB-IIIA NSCLC.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 16, 2022 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Lorlatinib Reduces CNS Progression in ALK-Positive NSCLC
(MedPage Today) -- Patients with previously untreated advanced ALK-positive non-small-cell lung cancer (NSCLC) experienced better outcomes with first-line lorlatinib (Lorbrena) versus crizotinib (Xalkori), regardless of whether they had brain metastases... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - June 15, 2022 Category: Hematology Source Type: news

ASCO: Ramucirumab Plus Pembrolizumab Promising in NSCLC
THURSDAY, June 9, 2022 -- Early research shows that overall survival is longer with ramucirumab and pembrolizumab (RP) compared with an investigator ' s choice standard-of-care (SOC) in advanced non-small cell lung cancer (NSCLC), according to a study... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 9, 2022 Category: Pharmaceuticals Source Type: news

European Commission approves Roche ’s Tecentriq as adjuvant treatment for a subset of people with early-stage non-small cell lung cancer
In the Phase III IMpower010 trial, adjuvantTecentriq reduced the risk of disease recurrence or death by 57% in people with PD-L1 high resected Stage II-III NSCLC, compared with best supportive careTecentriq is now the firstand only cancer immunotherapy available for certain people with early-stage NSCLC in EuropeToday ’s approval marksTecentriq ’s sixth lung cancer indication in EuropeBasel, 09 June 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has approved Tecentriq ® (atezolizumab) as an adjuvant treatment, following complete resection and platinum-based chemotherapy, for adu...
Source: Roche Investor Update - June 9, 2022 Category: Pharmaceuticals Source Type: news

U.S. FDA approves Foundation Medicine ’s FoundationOne®CDx as a companion diagnostic for Roche’s Rozlytrek® (entrectinib)
FoundationOneCDx can now be used to identify patients with ROS1 fusion-positive non-small cell lung cancer or patients with NTRK fusion-positive solidtumours for whom treatment withRozlytrek may be appropriateThis approval marks the first and only companion diagnostic indication forRozlytrek, and another important milestone intumour-agnostic approaches for people living with rare cancersRoche is a leader in drivingpersonalised healthcare around the world through validated diagnostic tools, genomic insights and a continued focus on drug developmentBasel, 9 June 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that ...
Source: Roche Media News - June 9, 2022 Category: Pharmaceuticals Source Type: news

European Commission approves Roche ’s Tecentriq as adjuvant treatment for a subset of people with early-stage non-small cell lung cancer
In the Phase III IMpower010 trial, adjuvantTecentriq reduced the risk of disease recurrence or death by 57% in people with PD-L1 high resected Stage II-III NSCLC, compared with best supportive careTecentriq is now the firstand only cancer immunotherapy available for certain people with early-stage NSCLC in EuropeToday ’s approval marksTecentriq ’s sixth lung cancer indication in EuropeBasel, 09 June 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has approved Tecentriq ® (atezolizumab) as an adjuvant treatment, following complete resection and platinum-based chemotherapy, for adu...
Source: Roche Media News - June 9, 2022 Category: Pharmaceuticals Source Type: news

Janssen Presents Initial Results from the Phase 2 RAGNAR Study of BALVERSA ® (erdafitinib) in Patients with Advanced Solid Tumors with FGFR Alterations
CHICAGO, ILLINOIS, June 7, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced initial results from the pivotal Phase 2 RAGNAR study evaluating the investigational use of BALVERSA® (erdafitinib), a fibroblast growth factor receptor (FGFR) kinase inhibitor, in patients with advanced solid tumors with prespecified FGFR alterations. At a planned interim analysis (IA), responses were observed across a variety of FGFR-driven solid tumors for patients who had exhausted standard treatment options prior to being treated with BALVERSA®.[1] These results will be featured in an oral presentation (...
Source: Johnson and Johnson - June 7, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news

Immunotherapy Rechallenge in NSCLC Yields Overall Survival Boost
(MedPage Today) -- CHICAGO -- Randomized data suggest that an anti-angiogenic agent can kick-start immunotherapy's antitumor activity in non-small cell lung cancer (NSCLC) patients whose disease has already progressed after chemotherapy and a... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - June 5, 2022 Category: Hematology Source Type: news

Adagrasib Shows Durable Benefit in KRAS-Mutated NSCLC Adagrasib Shows Durable Benefit in KRAS-Mutated NSCLC
Adagrasib shows durable clinical benefit in previously treated, advanced KRASG12C-mutated non-small cell lung cancer, including patients with brain metastases.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - June 4, 2022 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

KRAS Inhibitor Shrinks Tumors in Over 40% of NSCLC Patients
(MedPage Today) -- CHICAGO -- More than 40% of patients with KRAS G12C-mutated non-small cell lung cancer (NSCLC) responded to treatment with adagrasib, findings from a phase II trial showed. Among 112 evaluable patients in the KRYSTAL-1 study... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - June 4, 2022 Category: Hematology Source Type: news

Janssen to Highlight Science, Innovation and Advances in Robust Oncology Portfolio and Pipeline Through More Than 60 Data Presentations at ASCO and EHA
RARITAN, N.J., May 31, 2022 — The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that new research and data from its robust oncology portfolio and pipeline of investigational therapies will be presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place June 3-7 in Chicago, and the European Hematology Association (EHA) 2022 Congress taking place in Vienna, Austria, June 9-12. More than 60 presentations from company-sponsored studies across the two congresses, including 14 oral presentations, will feature new data and updates for both approved and investigation...
Source: Johnson and Johnson - May 31, 2022 Category: Pharmaceuticals Source Type: news

Accord Healthcare Adds Pemetrexed Lyo. Injection to Generic Drug Portfolio
DURHAM, N.C., May 27, 2022 -- (Healthcare Sales & Marketing Network) -- Accord Healthcare, Inc., a leading generic pharmaceutical company, has added Pemetrexed Lyo. Injection to its line of chemotherapy drugs. The new drug is formulated as a sterile lyoph... Biopharmaceuticals, Generics, Oncology Accord Healthcare, pemetrexed, ALIMTA , NSCLC (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - May 27, 2022 Category: Pharmaceuticals Source Type: news

Data at the 2022 ASCO Annual Meeting highlight Roche ’s continued commitment to innovation in oncology and personalised healthcare
Pivotal data onglofitamab, a potential first-in-class CD20xCD3 T-cell engaging bispecific antibody, in heavily pre-treated patients with aggressive lymphoma, will be presented as part of our industry-leadinghaematology portfolioFurther studies exploring broad genomic testing to support informed treatment decisions for patients and advance cancer care approaches will be presentedBasel, 24 May 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new data from clinical trials of 18 approved and investigational medicines across more than 20 cancer types will be presented at the 2022 American Society of Clinical Oncol...
Source: Roche Media News - May 24, 2022 Category: Pharmaceuticals Source Type: news